Related Experiment Video
Updated: Jun 23, 2026
06:56
Antibody Transfection into Neurons as a Tool to Study Disease Pathogenesis
Published on: September 26, 2012
Drug-induced anticentromere antibody?
1Second Department of Internal Medicine, Kaiser-Franz-Josef-Hospital, Vienna, Austria.
Zeitschrift Fur Rheumatologie
|March 1, 1989
Summary
Anticentromere antibody (ACA) can appear and disappear during D-penicillamine (DPA) treatment. This suggests that DPA may induce ACA formation in patients without related autoimmune conditions.
Area of Science:
- Immunology
- Rheumatology
- Pharmacology
Background:
- Anticentromere antibody (ACA) is a known serological marker for autoimmune diseases like CREST syndrome, progressive systemic sclerosis (PSS), Raynaud's syndrome (RS), and primary biliary cirrhosis (PBC).
- The diagnostic significance of ACA is primarily linked to these specific conditions.
Purpose of the Study:
- To investigate the potential for D-penicillamine (DPA) to induce Anticentromere antibody (ACA) formation.
- To observe ACA dynamics during DPA treatment in patients without established autoimmune markers.
Main Methods:
- Longitudinal observation of six patients undergoing D-penicillamine (DPA) treatment.
- Serological testing for Anticentromere antibody (ACA) during the course of DPA therapy.
Main Results:
- ACA was observed to appear and subsequently disappear in six patients during DPA treatment.
- These patients did not exhibit clinical or serological features of CREST, PSS, RS, PBC, or related syndromes.
- The fluctuating presence of ACA suggests a potential drug-induced phenomenon.
Conclusions:
- D-penicillamine (DPA) treatment may induce the formation of Anticentromere antibody (ACA).
- ACA can be transient and may occur in individuals without underlying autoimmune rheumatic diseases.
- This finding highlights the importance of considering drug-induced antibodies in serological diagnostics.
